» Articles » PMID: 32973959

USP22 Promotes Proliferation in Renal Cell Carcinoma by Stabilizing Survivin

Overview
Journal Oncol Lett
Specialty Oncology
Date 2020 Sep 25
PMID 32973959
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Renal cell carcinoma (RCC) is one of the commonest urological tumors. The incidence of RCC ranks third among urological tumors, after prostate cancer and bladder tumors. However, the etiology of RCC remains unclear. Ubiquitin-specific protease 22 (USP22), a potential marker of cancer stem cells, is associated with the occurrence and progression of numerous tumors. However, the roles of USP22 in RCC have not yet been investigated. Survivin is a member of the inhibitor of apoptotic protein family involved in RCC progression. The present study first detected the expression of USP22 and survivin in RCC tissues using immunohistochemistry and western blotting. It was revealed that the protein levels of USP22 and survivin in RCC tissues were higher than those in adjacent normal renal tissue. Subsequently, it was demonstrated that knockdown inhibited the growth of an RCC cell line ACHN and downregulated the protein level of survivin, accompanied by an increased level of cleaved-caspase-3. By contrast, overexpression of promoted the growth of ACHN cells, upregulated the expression of survivin and decreased the level of cleaved-caspase-3. Notably, the changes in USP22 expression did not affect the mRNA level. Finally, it was confirmed that USP22 interacted with survivin and stabilized it by downregulating its ubiquitination. The present results indicate that USP22 may regulate survivin via deubiquitination, thereby promoting the proliferation of RCC cells. The results of the current study suggest that USP22 may represent a novel therapeutic target for patients with RCC.

Citing Articles

Inhibition of SCF/USP22-dependent nuclear β-catenin ubiquitylation mediates cerebral ischemic tolerance.

Zuo Y, Xue J, Wen H, Zhan L, Chen M, Sun W Commun Biol. 2025; 8(1):214.

PMID: 39934243 PMC: 11814243. DOI: 10.1038/s42003-025-07644-5.


USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression.

Kowald L, Roedig J, Karlowitz R, Wagner K, Smith S, Juretschke T Cell Death Discov. 2024; 10(1):128.

PMID: 38467608 PMC: 10928094. DOI: 10.1038/s41420-024-01894-8.


Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis Targeting miR-485-5p/USP22 Axis in Osteosarcoma.

Chen T, Liu J, Zhang H, Li J, Shang G Front Oncol. 2022; 12:907472.

PMID: 35692754 PMC: 9179024. DOI: 10.3389/fonc.2022.907472.

References
1.
Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F . Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres. J Exp Clin Cancer Res. 2013; 32:13. PMC: 3602019. DOI: 10.1186/1756-9966-32-13. View

2.
Saenz D, Fiskus W, Manshouri T, Mill C, Qian Y, Raina K . Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2018; 33(6):1373-1386. DOI: 10.1038/s41375-018-0334-3. View

3.
Zeng F, Luo F, Lv S, Zhang H, Cao C, Chen X . A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway. Anticancer Drugs. 2014; 25(6):663-72. DOI: 10.1097/CAD.0000000000000091. View

4.
Kim P, Plescia J, Clevers H, Fearon E, Altieri D . Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003; 362(9379):205-9. DOI: 10.1016/S0140-6736(03)13910-4. View

5.
Liu T, Liu J, Chen Q, Jin S, Mi S, Shao W . Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma. Oncol Lett. 2019; 17(2):2040-2046. PMC: 6341666. DOI: 10.3892/ol.2018.9837. View